Vivos Therapeutics (VVOS) Cash from Operations (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Cash from Operations for 7 consecutive years, with -$3.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations rose 8.86% year-over-year to -$3.2 million in Q2 2026; TTM through Jun 2026 was -$17.2 million, a 19.44% decrease from a year earlier, with the FY2025 full-year figure at -$15.3 million, down 20.47% from the prior year.
• Cash from Operations was -$3.2 million for Q2 2026 at Vivos Therapeutics, up from -$6.0 million in the prior quarter.
• Over five years, Cash from Operations peaked at -$2.5 million in Q1 2024 and troughed at -$6.1 million in Q1 2022.
• A 5-year average of -$3.8 million and a median of -$3.5 million in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations surged 52.18% in 2023 and slumped 58.16% in 2026, its largest moves.
• Over 5 years, Cash from Operations stood at -$3.0 million in 2022, then increased by 8.47% to -$2.7 million in 2023, then decreased by 5.61% to -$2.9 million in 2024, then sank by 31.03% to -$3.8 million in 2025, then grew by 16.05% to -$3.2 million in 2026.
• The last three Cash from Operations figures came in at -$3.2 million (Q2 2026), -$6.0 million (Q1 2026), and -$3.8 million (Q4 2025), per Business Quant data.